Héctor Heras

Dr. Héctor Heras

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2021 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
Kostiantyn MarichevKostiantyn Marichev
Kostiantyn Marichev
SPSiddappa Patil
Siddappa Patil
SPShivaputra A Patil
Shivaputra A Patil
HHHéctor Heras
Héctor Heras
Alejandro BugarinAlejandro Bugarin
Alejandro Bugarin
Besides the well-established catalytic, synthetic and materials related applications of N-heterocyclic carbene (NHC) metal complexes, their use as therapeutics deserves a special attention. Many li...

1 January 2021 in Polyhedron
Verified
Journal Article
Closed access
HHHéctor Heras
Héctor Heras
ALAbby M. Lewis
Abby M. Lewis
SPShivaputra A. Patil
Shivaputra A. Patil
ABAlejandro Bugarin
Alejandro Bugarin

17 December 2024 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
HHHéctor Heras
Héctor Heras
EBEnrique Barragan
Enrique Barragan
Kostiantyn MarichevKostiantyn Marichev
Kostiantyn Marichev
DCDavid Chavez-Flores
David Chavez-Flores
Alejandro BugarinAlejandro Bugarin
Alejandro Bugarin
Isoindoline-1,3-dione, also referred as phthalimide, has gained recognition as promising pharmacophore due to the documented biological activities of its derivatives. Phthalimides are a family of synthetic molecules that exhibit notable bioactivity across various fields, particularly as anticancer and anti-inflammatory agents. This review focuses on syntheses and anti-inflammatory studies of the reported phthalimide derivatives. Although there are several synthetic protocols to produce phthalimide derivatives, two methods for synthesizing phthalimides are traditionally used: reacting phthalic anhydride with amines or anilines and the Gabriel synthesis. Due to their structural versatility and established pharmacological effects, derivatives of phthalimides such as the commercially available drugs thalidomide, pomalidomide, and lenalidomide, have driven the development of new derivatives offering hundreds of promising drug candidates with exceptional therapeutic potential, such as LASSBio 468 and adducts 2, 9, 150, 241, 255, and 305 to name some.

1 September 2021 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
SPSiddappa Patil
Siddappa Patil
SPShivaputra A Patil
Shivaputra A Patil
TFTemilade Fariyike
Temilade Fariyike
Kostiantyn MarichevKostiantyn Marichev
Kostiantyn Marichev
HHHéctor Heras
Héctor Heras
Alejandro BugarinAlejandro Bugarin
Alejandro Bugarin
Coumarins (2H-chromen-2-ones), also known as benzopyran-2-ones, are a family of naturally occurring heterocyclic ring systems that contain a lactone moiety. Coumarins exhibit a wide range of well-s... Graphical abstract This review focuses on the development of coumarins bearing azetidinone and thiazolidinone derivatives as potential antimicrobial, anticancer, antioxidant, antiviral, antitubercu...

20 June 2025 in Coordination Chemistry Reviews
Verified
Journal Article
Closed access
JMJack Moerschel
Jack Moerschel
EBEnrique Barragan
Enrique Barragan
HHHéctor Heras
Héctor Heras
ABAlejandro Bugarin
Alejandro Bugarin

20 January 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HHHéctor Heras
Héctor Heras
Blanca Sánchez-RamírezBlanca Sánchez-Ramírez
Blanca Sánchez-Ramírez
LMLinda Lucila Lucero Landeros Martinez
Linda Lucila Lucero Landeros Martinez
David Rodríguez GuerreroDavid Rodríguez Guerrero
David Rodríguez Guerrero
JEJosé C. Espinoza-Hicks
José C. Espinoza-Hicks
DCDavid Chavez-Flores
David Chavez-Flores
Background/Objectives: The development of specific inhibitors for cyclooxygenase-2 (COX-2) is a challenge for public health. A series of 17 N-phthalimide hybrids was evaluated using a functional M06 meta-GGA hybrid in combination with a polarized 6-311G (d, p) basis set. The top three candidates (6, 10, and 17) were synthesized and evaluated as selective COX-2 inhibitors of PGE-2 using an integrated in silico–in vitro approach. Methods: Molecular docking against COX-2 (PDB 5KIR) and COX-1 (PDB 6Y3C), supported by homology modeling and DFT geometry optimization (B3LYP/6-31G*), revealed that the phthalimide carbonyl groups and the 3,4,5-trimethoxyphenyl or geranyl-derived moieties establish key hydrogen bonds and hydrophobic contacts with Arg120, Tyr355, Tyr385, and Ser530 in the COX-2 active site, conferring predicted selectivity ΔGCOX−2 vs. COX−1 = −1.4 to −2.8 kcal/mol. Results: The compounds complied with Lipinski’s and Veber’s rules and displayed favorable ADMET profiles. In vitro assessment in LPS-stimulated J774A.1 murine macrophages confirmed potent inhibition of PGE2 production, 3.05 µg/mL, with compound 17 exhibiting the highest efficacy, 97.79 ± 5.02% inhibition at 50 µg/mL, and 10 showing 95.22 ± 6.03% inhibition at 50 µg/mL. Notably, all derivatives maintained >90% cell viability up to 250 µg/mL by resazurin assay and showed no evidence of cytotoxicity or mitosis potential in the tests at 24 h. Conclusions: These results demonstrate that strategic hybridization of phthalimide with natural and synthetic product-derived fragments yields highly potential PGE2 inhibitors. Therefore, compounds 6, 10, and 17 are promising lead candidates for the development of safer anti-inflammatory agents.